How to manage hypertension in a patient prescribed Vyvanse (lisdexamfetamine)?

Managing Hypertension in Patients Prescribed Vyvanse

Before prescribing Vyvanse to any patient, assess cardiovascular status and exclude serious cardiac disease, as CNS stimulants cause mean blood pressure increases of 2-4 mmHg and heart rate increases of 3-6 bpm, with some patients experiencing larger elevations. 1

Pre-Treatment Cardiovascular Assessment

Vyvanse is contraindicated in patients with known structural cardiac abnormalities, cardiomyopathy, serious cardiac arrhythmia, coronary artery disease, or other serious cardiac disease due to risk of sudden death. 1 Before initiating treatment:

• Obtain detailed cardiovascular history including symptoms of exertional chest pain, unexplained syncope, or other cardiac symptoms 1
• Measure baseline blood pressure and heart rate 1
• Consider ECG if cardiac risk factors present 1

Blood Pressure Monitoring During Vyvanse Treatment

Monitor blood pressure and heart rate at every visit in all patients taking Vyvanse, as stimulant-induced hypertension is a recognized cause of drug-induced secondary hypertension. 1, 2

• Check BP at baseline, after dose adjustments, and periodically during stable treatment 1
• Monitor for potential tachycardia and hypertension at each clinical encounter 1
• Use proper BP measurement technique following standardized protocols to avoid pseudoresistance 3

Managing Pre-Existing Hypertension

For Patients with Controlled Hypertension on Treatment:

Initiate standard antihypertensive therapy using ACE inhibitors, ARBs, dihydropyridine calcium channel blockers, or thiazide/thiazide-like diuretics as first-line agents, as these have demonstrated the most effective reduction in BP and cardiovascular events. 3

• Target systolic BP of 120-129 mmHg if well tolerated 3
• Use combination therapy (RAS blocker + CCB or diuretic) for most patients with confirmed hypertension (BP ≥140/90 mmHg) 3
• Preferably use fixed-dose single-pill combinations to improve adherence 3
• Continue monitoring BP closely after starting Vyvanse, as additional antihypertensive adjustments may be needed 1

For Patients Who Develop Hypertension on Vyvanse:

First exclude pseudoresistance (poor measurement technique, white coat effect, nonadherence) and confirm sustained elevation with out-of-office BP monitoring before intensifying treatment. 3

If BP remains elevated (≥140/90 mmHg):

• Initiate combination antihypertensive therapy with a RAS blocker (ACE inhibitor or ARB) plus either a dihydropyridine CCB or thiazide/thiazide-like diuretic 3
• Consider whether Vyvanse is essential for the patient's ADHD management versus alternative non-stimulant options 1
• If BP control requires three drugs, add a thiazide/thiazide-like diuretic to the RAS blocker and CCB combination 3

Resistant Hypertension on Vyvanse

If BP remains >140/90 mmHg despite three optimally dosed antihypertensive medications including a diuretic, first exclude substance-induced hypertension (confirm Vyvanse as potential contributor) and pseudoresistance before adding fourth-line agents. 3

Management approach:

• Add low-dose spironolactone (25-50 mg daily) as fourth-line agent if serum potassium <4.5 mmol/L and eGFR >45 ml/min/1.73m² 3
• Alternative fourth-line agents if spironolactone contraindicated: eplerenone, amiloride, doxazosin, or beta-blockers 3
• Refer to specialist hypertension center for management of resistant hypertension 3
• Strongly consider discontinuing Vyvanse if it is the primary driver of resistant hypertension 2

Critical Safety Considerations

Instruct patients to immediately contact their healthcare provider if they develop exertional chest pain, unexplained syncope, or other symptoms suggestive of cardiac disease while taking Vyvanse. 1

Common Pitfalls to Avoid:

• Do not combine two RAS blockers (ACE inhibitor + ARB), as this is not recommended and provides no additional benefit 3
• Avoid beta-blockers as first-line monotherapy unless compelling indication exists (post-MI, angina, heart failure with reduced ejection fraction, or heart rate control) 3
• Do not use intravenous hydralazine for non-urgent BP elevations in hospitalized patients on Vyvanse, as it causes highly variable BP responses and risk of hypotension 4
• Ensure patients take antihypertensive medications at the same time daily to establish routine and improve adherence 3

Lifestyle Modifications:

Implement comprehensive lifestyle interventions concurrently with pharmacological therapy, as these may allow subsequent medication down-titration. 3

• Weight reduction to ideal body weight if obese 3, 5
• Restrict sodium intake by eliminating table salt 3, 5
• Limit alcohol to <21 units/week (males) or <14 units/week (females) 3
• Regular aerobic exercise 3, 5
• Smoking cessation (critical, as smoking risk outweighs mild hypertension risk) 3
• Restrict free sugar consumption, especially sugar-sweetened beverages, to <10% of energy intake 3

When to Discontinue Vyvanse

Consider discontinuing Vyvanse if BP cannot be controlled despite optimal three-drug antihypertensive therapy, or if patient develops hypertensive urgency/emergency. 3, 1 Evaluate alternative ADHD treatments including non-stimulant options in such cases.